Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Drug Manufacturers - Specialty & Generic

Healthcare
$4.78 +0.14%

+$0.01 today

Market cap
$791.33M
Beta
0.24
P/E (TTM)
5.6
EPS (TTM)
$0.63
52W Low $0.66High $5.78

Volume 2.22M

Average 2.35M

IRWD Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Ironwood Pharmaceuticals, Inc.NASDAQ: IRWD

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 103.2% from a year ago

Cash & equivalents stood at $220.47M at the end of Q1 FY2026, up 103.2% from a year earlier and up 2.3% from the prior quarter. Over 3 fiscal years it compounded at -31.0% a year.

Context

  • Cash & equivalents amounted to 50.7% of total assets at the end of Q1 FY2026, up 17.6 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +103.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$220.47M+2.3% QoQ
Last fiscal yearDec 2025
$215.46M+143.3% YoY
Year agoMar 2025
$108.48M+103.2% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103.2%——
1 year+143.3%——
3-year CAGR-31.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
215.46M USD
Year-over-year change
+143.3%
4-year CAGR
-23.2%

Cash & Equivalents vs competitors

How IRWD compares with its peers on the latest reported figures

  • IRWD's Mar 2026 cash & equivalents of $220.47M is the highest of the 3 companies compared; the peer median is $56.97M.
  • Its year-over-year change of +103.2% is the highest of 3, against a peer median of +14.4%.
  • Cash & equivalents amounts to 50.7% of total assets for IRWD, versus a peer median of 6.9%.
IRWD Competitors Peer median
Cash & Equivalents for IRWD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRWDIronwood Pharmaceuticals, Inc.Mar 2026$220.47M +103.2%-31.0%50.7%
SYRESpyre Therapeutics, Inc.Sep 2026$82.73M +27.5%+35.0%7.5%
ARDXArdelyx, Inc.Mar 2026$31.21M +1.3%-10.9%6.2%
Peer median (excluding IRWD) $56.97M+14.4%+12.0%6.9%

Competitors are the stored peer set for IRWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents620.13M656.2M92.15M88.56M215.46M
Short-term Investments00000
Net Receivables114.04M115.46M129.12M81.89M46.75M
Inventory01.25M000
Other Current Assets2.37M0011.92M11.98M
Total Current Assets745.23M780.63M233.29M182.37M274.18M
Property, Plant & Equipment (Net)22.93M20.31M18.17M15.52M12.75M
Goodwill00000
Intangible Assets003.68M2.86M2.04M
Long-term Investments015.07M000
Tax Assets333.29M283.66M212.32M144.23M103.43M
Other Non-current Assets25.48M847K3.61M5.92M4.5M
Total Non-current Assets381.7M319.89M237.79M168.54M122.72M
Total Assets1.13B1.1B471.07M350.91M396.9M
Account Payables935K483K7.83M2.13M2.9M
Short-term Debt116.86M0199.56M0199.68M
Tax Payables0656K1.24M521K0
Deferred Revenue002.62M2.03M1.11M
Other Current Liabilities7.49M15.88M26.13M4.98M21M
Total Current Liabilities161.7M25.53M276.1M38.85M242.22M
Long-term Debt337.33M396.25M498.31M583.99M385M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities3.5M9.77M28.42M17.11M21.65M
Total Non-current Liabilities359.32M422.62M541.27M613.4M416.52M
Total Liabilities521.02M448.14M817.37M652.24M658.74M
Common Stock162K154K156K160K163K
Retained Earnings(937.61M)(696.38M)(1.7B)(1.7B)(1.67B)
Accumulated OCI(0)0(3.03M)923K(1.06M)
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity605.91M652.38M(346.3M)(301.34M)(261.83M)
Total Debt475.8M415.92M715.54M599.48M597.8M
Net Debt(144.33M)(240.29M)623.38M510.92M382.35M

Ironwood Pharmaceuticals, Inc.

NASDAQ:IRWD

Intrinsic Alpha fair value

Locked

Current Price

$4.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.